Global Xerostomia Therapeutics Market

Global Xerostomia Therapeutics Market Size, Trends & Analysis - Forecasts to 2026 By Product (Salivary Stimulants, Salivary Substitutes, and Dentifrices), By Type (OTC and Prescription), By Region (North America, Asia Pacific, CSA, Europe, and The Middle East and Africa); Competitive Landscape, Company Market Share Analysis, and Competitor Analysis

Category Healthcare
Format
  • ms word
  • ms excel
  • ms ppt
  • pdf
This report was recently updated on May 17 2024 with the latest and most recent market numbers

Xerostomia Therapeutics Market Insights

Xerostomia is characterized as dry mouth caused by decreased or absent saliva flow. Xerostomia is a symptom of toxicity caused by chemotherapy, head, neck radiotherapy, drug side effects, autoimmune illness, or other diseases such as untreated asthma, viruses, and hormonal shifts. Xerostomia is normal in people who have Sjögren's syndrome or are undergoing radiation treatment for head and neck cancer. Xerostomia is a typical condition among the elderly, affecting approximately 20% of the global population. Additionally, xerostomia causes reduced salivary flow can make it significantly difficult to taste, chew, swallow, and speak; it can also increase the risk of developing dental decay, tooth demineralization, tooth irritation, and oral infections.

The expanded use of radiation therapy and chemotherapy is anticipated to accelerate the prevalence of xerostomia, which is presumed to stimulate the xerostomia therapeutics market. Key drivers influencing market growth encompass increasing prescription drug use, convenient accessibility & cost-effectiveness of drugs, a rising senile demographic pool, and an uptick in the incidence of disorders such as Sjogren's syndrome, HIV, diabetes, and Alzheimer's disease, among others. Furthermore, considerations including the lack of knowledge & the absence of appropriate treatment options are likely to impede the use of xerostomia therapeutics drugs and can serve as a limiting force for the xerostomia therapeutics market.

The major market drivers in the market of xerostomia therapeutics are the increasing incidence of related diseases, the most prevalent of which is Sjogren's syndrome, which is driving the rise of xerostomia. Sjogren's disease affects about 3.1 million people out of a total population of 4 million, according to the American College of Rheumatology. However, the xerostomia care demand may be slowed by factors such as a lack of understanding among people in emerging and underdeveloped countries. Another factor impeding the development of the xerostomia care market is the scarcity of successful treatments.

The intensified use of chemotherapy and radiotherapy in cancer care may harm the salivary glands. As a result, this has been a major cause for people seeking xerostomia treatments. The increase in diabetes cases globally has an effect on the salivary glands. Furthermore, taking medications can cause a variety of adverse effects, one of which is dry mouth. As a result, individuals are becoming more reliant on drugs, which is leading to the development of the xerostomia therapeutics market. Increasing self-reliance and understanding of the current situation is also fostering business development.

Some of the main forces driving demand growth are an expansion in attractive payout policies for xerostomia drugs, and also an uptick in responsiveness and knowledge regarding conditions correlated with the disease. The rising prevalence of xerostomia, as well as related clinical ailments such as Parkinson's disease, high blood pressure, Sjogren's syndrome, and diabetes, benefits the global market of xerostomia therapeutics. As per the Colgate-Palmolive Company, it is forecasted that more than 25 million individuals in the United States suffer from dry mouth. Likewise, the Sjogren Syndrome Foundation reports that more than four million individuals have Sjogren's syndrome, which is one of the disorders that trigger dry mouth. Conversely, in order to address this issue, this foundation conducts outreach campaigns in the United States for individuals who are recovering from this disease, as well as to empower the common population. This consideration has also contributed to the overall demand in this region's growth. Along with various foundations raising public consciousness, several large pharmaceutical firms are pursuing acquisitions & joint ventures with new corporations in order to expand their product offerings and raise public consciousness, thereby further propelling the global demand.

global xerostomia therapeutics market

Xerostomia Therapeutics Market: By Product

Based on the products, the market of xerostomia therapeutics is divided into salivary stimulants, salivary substitutes, dentifrices in this market. The dentifrices category led the overall market in terms of sales due to its efficiency, availability, cost-effectiveness, and higher penetration among primary consumers. Salivary stimulants are predicted to rise the fastest throughout the forecast period. Salivary stimulants are available in a multitude of varieties, including mints, sugar-free chewing gums, sprays, and lozenges. Patients have easy accessibility to a broad variety of alternatives for each product. Both of the above considerations are foreseen to contribute to the segment's development.

Xerostomia Therapeutics Market: By Type

Based on the type, the xerostomia therapeutics market is categorized as OTC and Prescription. In terms of volume, the OTC segment contributed to the largest share and is foreseen to rise at a profitable CAGR throughout the forecast period. The supremacy is due to its vast range & affordability, protection & effectiveness, restricted availability of generic medications, and low product prices. Moreover, one of the market's primary driving factors is the easy availability of low-cost prescription OTC products, namely, mouthwashes, saliva replacement gels, sugar-free chewing gums, lozenges, toothpaste, and oral-adhering discs, pads, and melts.

asia pacific xerostomia therapeutics market

Xerostomia Therapeutics Market: By Region

As per the geographical analysis, the market can be classified into North America (the US, Canada, and Mexico), Asia Pacific (India, China, Japan, Malaysia, Singapore, and Rest of Asia Pacific), Europe (Germany, United Kingdom, Italy, France, Spain, Netherlands, and Rest of Europe), Middle East & Africa and Central & South America. North America is likely to lead in the geographic category with the highest sales share and it is followed by Europe. The growing incidence of xerostomia and several dry mouth-related conditions like Sjogren's syndrome, rheumatoid arthritis, and HIV, along with an uptick in dry mouth literacy campaigns are primary variables leading to supremacy. For example, the Sjogren Syndrome Foundation of the United States is in charge of promoting consciousness and assisting patients with xerostomia in the United States and Canada. Due to considerations such as increasing healthcare spending, a rise in awareness-raising campaigns, and the proliferation of diseases including diabetes, HIV, cancer, and Parkinson's disease which trigger dry mouth complications, the Asia-Pacific region is presumed to record a lucrative CAGR throughout the forecast period.

Xerostomia Therapeutics Market Share and Competitor Analysis

GlaxoSmithKline PLC, Church & Dwight Co., Inc., Colgate-Palmolive Company, Hikma Pharmaceuticals PLC, Pendopharm, Sun Pharmaceuticals Industries Ltd., Lupin Pharmaceuticals, Inc., Pfizer, Inc., Parnell Pharmaceuticals, Inc., Acacia Pharma, and OraCoat are the major players in the xerostomia therapeutics market.

Please note: This is not an exhaustive list of companies profiled in the report.

Chapter 1   Methodology

1.1    Market Scope & Definitions

1.2    Estimates & Forecast Calculation

1.3    Historical Data Overview And Validation

1.4    Data Sources

1.4.1    Secondary

1.4.2    Primary

Chapter 2   Report Outlook

2.1    Xerostomia Therapeutics Market Overview, 2016-2026

2.1.1    Industry Overview

2.1.2    Product Overview

2.1.3    Type Overview

          2.1.4    Regional Overview

Chapter 3   Xerostomia Therapeutics Market Trends

3.1    Market Segmentation

3.2    Industry Background, 2016-2026

3.3    Market Key Trends

3.3.1    Positive Trends

3.3.1.1    Growing Prevalence of Diseases Such as Sjogren’s Syndrome, HIV, Diabetes, Alzheimer’s Disease, and Others.

3.3.1.2    Increasing Adoption of Chemotherapy and Radiotherapy in Cancer Treatment

3.3.2    Industry Challenges

3.3.2.1    Growing Emergence Novel Alternative

3.4    Prospective Growth Scenario

3.4.1    Product Growth Scenario

3.4.2    Type Growth Scenario

3.5    COVID-19 Influence over Industry Growth

3.6    Porter’s Analysis

3.7    PESTEL Analysis

3.8    Value Chain & Supply Chain Analysis

3.9    Regulatory Framework

3.9.1    North America

3.9.2    Europe

3.9.3    APAC

3.9.4    LATAM

3.9.5    MEA

3.10    Technology Overview

3.11    Market Share Analysis, 2020

3.11.1    Company Positioning Overview, 2020

Chapter 4   Xerostomia Therapeutics Market, By Product

4.1    Product Outlook

4.2    Salivary Stimulants

4.2.1    Market Size, By Region, 2016-2026 (USD Million)

4.3    Salivary Substitutes

          4.3.1    Market Size, By Region, 2016-2026 (USD Million)

4.4    Dentifrices

          4.4.1    Market Size, By Region, 2016-2026 (USD Million)

Chapter 5   Xerostomia Therapeutics Market, By Type

5.1    Type Outlook

5.2     OTC

5.2.1    Market Size, By Region, 2016-2026 (USD Million)

5.3    Prescription

          5.3.1    Market Size, By Region, 2016-2026 (USD Million)

Chapter 6 Xerostomia Therapeutics Market, By Region

6.1    Regional outlook

6.2    North America

6.2.1    Market Size, By Country 2016-2026 (USD Million)

6.2.2    Market Size, By Product, 2016-2026 (USD Million)

6.2.3    Market Size, By Type, 2016-2026 (USD Million)

6.2.4    U.S.

6.2.4.1    Market Size, By Product, 2016-2026 (USD Million)

6.2.4.2    Market Size, By Type, 2016-2026 (USD Million)

6.2.5    Canada

6.2.5.1    Market Size, By Product, 2016-2026 (USD Million)

6.2.5.2    Market Size, By Type, 2016-2026 (USD Million)

6.3    Europe

6.3.1    Market Size, By Country 2016-2026 (USD Million)

6.3.2    Market Size, By Product, 2016-2026 (USD Million)

6.3.3    Market Size, By Type, 2016-2026 (USD Million)

6.3.4    Germany

6.3.4.1    Market Size, By Product, 2016-2026 (USD Million)

6.3.4.2    Market Size, By Type, 2016-2026 (USD Million)

6.3.5    UK

6.3.5.1    Market Size, By Product, 2016-2026 (USD Million)

6.3.5.2    Market Size, By Type, 2016-2026 (USD Million)

6.3.6    France

6.3.6.1    Market Size, By Product, 2016-2026 (USD Million)

6.3.6.2    Market Size, By Type, 2016-2026 (USD Million)

6.3.7    Italy

6.3.7.1    Market Size, By Product, 2016-2026 (USD Million)

6.3.7.2    Market Size, By Type, 2016-2026 (USD Million)

6.3.8   Spain

6.3.8.1    Market Size, By Product, 2016-2026 (USD Million)

6.3.8.2    Market Size, By Type, 2016-2026 (USD Million)

6.3.9    Russia

6.3.9.1    Market Size, By Product, 2016-2026 (USD Million)

6.3.9.2    Market Size, By Type, 2016-2026 (USD Million)

6.4    Asia Pacific

6.4.1    Market Size, By Country 2016-2026 (USD Million)

6.4.2    Market Size, By Product, 2016-2026 (USD Million)

6.4.3    Market Size, By Type, 2016-2026 (USD Million)

6.4.4    China

6.4.4.1    Market Size, By Product, 2016-2026 (USD Million)

6.4.4.2    Market Size, By Type, 2016-2026 (USD Million)

6.4.5    India

6.4.5.1    Market Size, By Product, 2016-2026 (USD Million)

6.4.5.2    Market Size, By Type, 2016-2026 (USD Million)

6.4.6    Japan

6.4.6.1    Market Size, By Product, 2016-2026 (USD Million)

6.4.6.2    Market Size, By Type, 2016-2026 (USD Million)

6.4.7    Australia

6.4.7.1    Market Size, By Product, 2016-2026 (USD Million)

6.4.7.2    Market size, By Type, 2016-2026 (USD Million)

6.4.8    South Korea

6.4.8.1    Market Size, By Product, 2016-2026 (USD Million)

6.4.8.2    Market Size, By Type, 2016-2026 (USD Million)

6.5    Latin America

6.5.1    Market Size, By Country 2016-2026 (USD Million)

6.5.2    Market Size, By Product, 2016-2026 (USD Million)

6.5.3    Market Size, By Type, 2016-2026 (USD Million)

6.5.4    Brazil

6.5.4.1    Market Size, By Product, 2016-2026 (USD Million)

6.5.4.2    Market Size, By Type, 2016-2026 (USD Million)

6.5.5    Mexico

6.5.5.1    Market Size, By Product, 2016-2026 (USD Million)

6.5.5.2    Market Size, By Type, 2016-2026 (USD Million)

6.5.6    Argentina

6.5.6.1    Market Size, By Product, 2016-2026 (USD Million)

6.5.6.2    Market Size, By Type, 2016-2026 (USD Million)

6.6    MEA

6.6.1    Market Size, By Country 2016-2026 (USD Million)

6.6.2    Market Size, By Product, 2016-2026 (USD Million)

6.6.3    Market Size, By Type, 2016-2026 (USD Million)

6.6.4    Saudi Arabia

6.6.4.1    Market Size, By Product, 2016-2026 (USD Million)

6.6.4.2    Market Size, By Type, 2016-2026 (USD Million)

6.6.5    UAE

6.6.5.1    Market Size, By Product, 2016-2026 (USD Million)

6.6.5.2    Market Size, By Type, 2016-2026 (USD Million)

6.6.6    South Africa

6.6.6.1    Market Size, By Product, 2016-2026 (USD Million)

6.6.6.2    Market Size, By Type, 2016-2026 (USD Million)

Chapter 7 Company Landscape

7.1    Competitive Analysis, 2020

7.2    GlaxoSmithKline PLC

          7.2.1    Company Overview

7.2.2    Financial Analysis

7.2.3    Strategic Positioning

7.2.4    Info Graphic Analysis

7.3    Church & Dwight Co., Inc.

7.3.1    Company Overview

7.3.2    Financial Analysis

7.3.3    Strategic Positioning

7.3.4    Info Graphic Analysis

7.4    Colgate-Palmolive Company

7.4.1    Company Overview

7.4.2    Financial Analysis

7.4.3    Strategic Positioning

7.4.4    Info Graphic Analysis

7.5    Hikma Pharmaceuticals PLC

7.5.1    Company Overview

7.5.2    Financial Analysis

7.5.3    Strategic Positioning

7.5.4    Info Graphic Analysis

7.6    Pendopharm

7.6.1    Company Overview

7.6.2    Financial Analysis

7.6.3    Strategic Positioning

7.6.4    Info Graphic Analysis

7.7    Sun Pharmaceuticals Industries Ltd.

7.7.1    Company Overview

7.7.2    Financial Analysis

7.7.3    Strategic Positioning

7.7.4    Info Graphic Analysis

7.8    Lupin Pharmaceuticals, Inc.

7.8.1    Company Overview

7.8.2    Financial Analysis

7.8.3    Strategic Positioning

7.8.4    Info Graphic Analysis

7.9    Pfizer, Inc.

7.9.1    Company Overview

7.9.2    Financial Analysis

7.9.3    Strategic Positioning

7.9.4    Info Graphic Analysis

7.10    Parnell Pharmaceuticals, Inc.

7.10.1    Company Overview

7.10.2    Financial Analysis

7.10.3    Strategic Positioning

7.10.4    Info Graphic Analysis

7.11    Acacia Pharma

7.11.1    Company Overview

7.11.2    Financial Analysis

7.11.3    Strategic Positioning

7.11.4    Info Graphic Analysis

7.12    OraCoat

7.12.1    Company Overview

7.12.2    Financial Analysis

7.12.3    Strategic Positioning

7.12.4    Info Graphic Analysis

7.13    Other Companies

7.13.1    Company Overview

7.13.2    Financial Analysis

7.13.3    Strategic Positioning

7.13.4    Info Graphic Analysis

The Global Xerostomia Therapeutics Market has been studied from the year 2019 till 2026. However, the CAGR provided in the report is from the year 2021 to 2026. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.

The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Xerostomia Therapeutics Market.

The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.

Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.

We value your investment and offer free customization with every report to fulfil your exact research needs.
This website is secure and your personal details are safe. Privacy
You can also purchase parts of this report. Do you want to check out a section wise price list?

Tailor made solutions just for you

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

OUR CLIENTS

  • Client of Global Market Estimates - Fedex
  • Client of Global Market Estimates - Samsung
  • Client of Global Market Estimates - Siemens
  • Client of Global Market Estimates - Lonza
  • Client of Global Market Estimates - DuPont
  • Client of Global Market Estimates - Medtronic
  • Client of Global Market Estimates - Toray
  • Client of Global Market Estimates - Signify
  • Client of Global Market Estimates - Teledyne
  • Client of Global Market Estimates - Trelleborg
  • Client of Global Market Estimates - Kikkoman Biochemifa
  • Client of Global Market Estimates - Leoni
  • Client of Global Market Estimates - Molnlycke
  • Client of Global Market Estimates - Spirent
  • Client of Global Market Estimates - Tokyo Electron Limited
  • Client of Global Market Estimates - Aranca
  • Client of Global Market Estimates - Asahi Kasei
  • Client of Global Market Estimates - Chimai
  • Client of Global Market Estimates - Grapsud
  • Client of Global Market Estimates - Horiba
  • Client of Global Market Estimates - Indorama
  • Client of Global Market Estimates - L&T
  • Client of Global Market Estimates - Integralife
  • Client of Global Market Estimates - Synamedia
  • Client of Global Market Estimates - Sorrento Therapeutics
  • Client of Global Market Estimates - Solenis
  • Client of Global Market Estimates - Sartorius